Shares of LEADS BIOLABS-B (09887) have surged by over 11% today, extending a rally that has seen the stock gain more than 30% over the past three trading sessions.

As of the latest update, the stock is up 11.45% to HK$67.15, with a trading turnover of HK$166 million.

Key Developments Driving Momentum

The recent upward movement follows the company's announcement regarding the 2026 European Society for Medical Oncology (ESMO) congress. It has been confirmed that six of its latest research achievements have been selected for presentation.

Notably, this includes two high-profile oral presentations, with the potential for a late-breaking abstract (LBA) to be added in September.

In a separate development, the company announced that LBL-024 for first-line non-small cell lung cancer (1L NSCLC) has been selected for an oral presentation at the World Conference on Lung Cancer (WCLC) scheduled for this September.

Significant Regulatory Progress

Adding to the positive news flow, the company recently disclosed that the new drug application for its core asset, LBL-024, has been granted priority review status.

The company stated that this milestone formally locks in the commercialization timeline for its product, with a clear and anticipated path to market approval.

Concurrently, the company is actively advancing all necessary commercial preparations ahead of the anticipated launch.